Resources by service
$5M Saved for Top 20 Global Pharma Company with Almac Supply Chain Oversight
One of the top 20 global pharmaceutical companies conducted a phase III clinical trial to compare the efficacy, safety, and tolerability of multiple doses of Investigational Medicinal Products (IMPs) with a comparator drug product for the treatment of Diabetes.
At mid-trial, they engaged Almac’s Supply Chain Management (SCM) experts to devise a new optimal drug supply strategy to prevent further stock-outs. The study was a randomised, double-blinded, parallel group trial. This was a truly global phase III trial with 44 countries participating across Europe, United States, Latin America, Asia and Africa.
Almac faced a number of significant challenges to maintain and optimise the IMP supply chain. The SCM assigned conducted a full review of historical patient event data from the Interactive Response Technology (IRT) report, and identified trend in dose titrations from patients enrolled in the study.
Almac saved the client $4.95 million per year while preventing further stock-outs.
Click here to discover more about Almac Clinical Services
*By submitting your information you acknowledge that you have read the privacy statement and you consent to our processing the data in accordance with that privacy statement. We may, from time to time, send you material relevant to your interests. If you change your mind at any time about wishing to receive material from us, you can send an email to email@example.com. Every email we send you will also include an unsubscribe link so you can unsubscribe from our marketing list.